Dihexa

Dihexa is a small synthetic peptide derivative of angiotensin IV, developed by Washington State University researchers Joseph Harding and colleagues. It is studied as a potent enhancer of hepatocyte growth factor (HGF) signaling, which influences synaptic plasticity and neuron repair. In animal research, Dihexa has shown remarkable cognitive-enhancing effects at very low doses, leading to widespread interest in the nootropic community. It is sold strictly for laboratory research.

Dihexa is a tiny modified peptide that, in rodent studies, dramatically restored learning and memory in models of cognitive impairment — at doses far lower than most peptides. The mechanism is unusual: it amplifies the action of hepatocyte growth factor (HGF), which normally helps grow new synaptic connections. That's why it gets called the 'synapse-builder' peptide. It is one of the more potent and intriguing research peptides in the cognitive space, but human clinical data is still very limited.

Dihexa appears to enhance the binding of HGF to its receptor c-Met, increasing downstream signaling that supports synaptogenesis — the formation of new synapses between neurons. In Alzheimer's animal models, Dihexa restored spatial memory performance and increased dendritic spine density. It is orally bioavailable and crosses the blood-brain barrier, which is rare for a peptide.

• •Alzheimer's disease animal models
• •Synaptogenesis and dendritic spine density
• •HGF/c-Met signaling enhancement
• •Spatial and working memory performance
• •Age-related cognitive decline

Dihexa has a loyal following on nootropic forums — r/Nootropics, LongeCity — and is treated as one of the more potent peptide-based cognitive enhancers. Users frequently note that effects build over weeks, not minutes, and that subjective effects vary widely. Discussion also acknowledges safety unknowns: HGF/c-Met signaling has tumor-growth implications, and long-term safety in humans is essentially unstudied.

“The synapse-builder peptide.”

Dihexa is most commonly stacked with Semax for daytime focus, NSI-189 (a research antidepressant), or in 'neurogenesis stacks' alongside Cerebrolysin cycles.

Dihexa is a small synthetic peptide that enhances HGF/c-Met signaling and promotes synaptogenesis in animal models of cognitive impairment. It is potent at low doses, orally bioavailable, and has limited human safety data — sold strictly for laboratory research.